This book includes a plain text version that is designed for high accessibility. To use this version please follow this link.
11-08 :: August 2011


nanotimes


Companies Facts


N


anophase Technologies Corporation (NASDAQ: NANX) reported financial results for the second quarter and six-month period ended June 30, 2011.


Nanophase CEO and President Jess Jankowski com- mented. “Year-to-date revenue is ahead of last year and we believe that gap will grow as we move through the second half of 2011. We look to post unusually steady performance for our company, at a higher level than last year, which was significantly better than the year before that.”


Revenue for the second quarter was $2.9 million, down approximately $0.4 million from the second quarter of 2010, which happened to be the highest revenue level reported during 2010. Second quarter 2011 revenue of $2.9 million exceeded first quarter 2011 revenue of $2.8 million, as well as three of the four quarters of 2010. Gross margin for the quarter was $1.0 million, or 34% of revenue, slightly below the 36% posted during the second quarter of 2010. The net loss for the quarter was $0.5 million, or a loss of $0.02 per share, which compares to a net loss of $0.1 million, or $0.01 per share, for the second quarter of 2010.


The balance sheet is strong with approximately $3.5 million in cash and cash equivalents. The Company has no debt.


http://www.nanophase.com N


anostart AG (OTCQX: NASRY) is increasing its stake in Singapore-based Microlight Sensors


to 31%. This stems from payment of a second tran- che from the round of financing concluded back in


2010. The additional funds will go into commercial expansion, in particular buildup of marketing and sales structures in Asia, seed financing for orders and projects, and development of innovative sensor technologies. Founded in 2006, Microlight Sensors develops optical systems, instruments, and compon- ents for optical sensor technologies.


http://www.nanostart.de http://www.nanostart-asia.com


N


anoString Technologies, Inc., announced the availability of the nCounter®


39


Rat miRNA Expres-


sion Assay Kit for use on its nCounter Analysis Sy- stem. The nCounter Rat miRNA Expression Assay Kit enables researchers to perform direct digital detec- tion and counting of tissue-specific miRNAs at single- base resolution, without the need for amplification. The kit provides the capacity to perform multiplexed profiling of more than 400 rat miRNAs in a single tube, with specificity and sensitivity comparable to qPCR. Like all nCounter assays, the kit is compatible with multiple sample types, including FFPE samples.


Moreover, the Company is initiating the first in a series of studies to evaluate the clinical utility of the NanoString Breast Cancer Intrinsic Subtyping Assay. The initial investigation will utilize samples from the TransATAC study to evaluate whether the assay, which is based on the PAM50 gene signature, can quantitate the probability of cancer recurrence in individual post-menopausal women with hormone receptor-positive, early stage breast cancer (ESBC) who have been treated with hormonal therapy.


http://www.NanoString.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103